Quetiapine and Norquetiapine in Plasma and Cerebrospinal Fluid of Schizophrenic Patients Treated With Quetiapine: Correlations to Clinical Outcome and HVA, 5-HIAA, and MHPG in CSF

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2010-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/JCP.0b013e3181f2288ePMID 20814316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and validation of an LC-MS/MS method for the determination of quetiapine and four related metabolites in human plasma.

  2010cited by this paper
• Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.

  2009cited by this paper
• N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity

  2008cited by this paper
• Quetiapine: dose-response relationship in schizophrenia.

  2008cited by this paper
• Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.

  2007cited by this paper
• Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients

  2007cited by this paper
• Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

  2007cited by this paper
• Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

  2007cited by this paper
• Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study.

  2007cited by this paper
• Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

  2007cited by this paper
• The Clinical Relevance of Percentage Improvements on the PANSS Score

  2007cited by this paper
• Clinical Pharmacokinetics of Atypical Antipsychotics

  2007cited by this paper
• Five‐year follow‐up during antipsychotic treatment: efficacy, safety, functional and social outcome

  2007cited by this paper
• Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain.

  2007cited by this paper
• Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

  2006cited by this paper
• Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein

  2006cited by this paper
• The role of dopamine and norepinephrine in depression and antidepressant treatment.

  2006cited by this paper
• Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder.

  2006cited by this paper
• Bipolar depression: a new role for atypical antipsychotics?

  2005cited by this paper
• Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

  2005cited by this paper
• Atypicality of atypical antipsychotics.

  2005cited by this paper
• A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.

  2005cited by this paper
• Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

  2004cited by this paper
• Atypical Antipsychotics: Matching Receptor Profile to Individual Patient's Clinical Profile

  2004influential reference
• Therapeutic Monitoring of New Antipsychotic Drugs

  2004cited by this paper
• A systematic review of atypical antipsychotic drugs in schizophrenia.

  2003cited by this paper
• Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia

  2003cited by this paper
• In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

  2002cited by this paper
• Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs

  2002cited by this paper
• PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium.

  2002cited by this paper
• Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting

  2002cited by this paper
• Clinical Pharmacokinetics of Quetiapine

  2001cited by this paper
• The Effect of Olanzapine Treatment on Monoamine Metabolite Concentrations in the Cerebrospinal Fluid of Schizophrenic Patients

  2001cited by this paper
• Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.

  2000cited by this paper
• The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.

  2000cited by this paper
• A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.

  2000cited by this paper
• History and evolution of the monoamine hypothesis of depression.

  2000cited by this paper
• Review of quetiapine and its clinical applications in schizophrenia

  2000cited by this paper
• Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.

  1999cited by this paper
• CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia.

  1998cited by this paper
• Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

  1997cited by this paper
• A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

  1997cited by this paper
• Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia.

  1997cited by this paper
• SKID I. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Interviewheft und Beurteilungsheft. Eine deutschsprachige, erweiterte Bearb. d. amerikanischen Originalversion des SKID I

  1997cited by this paper
• A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms

  1996cited by this paper
• Clozapine therapy and increases in homovanillic acid.

  1995cited by this paper
• Intercellular communication in the brain: wiring versus volume transmission.

  1995cited by this paper
• Concurrent analysis of neuropeptides and biogenic amines in brain tissue of rats treated with electroconvulsive stimuli.

  1995cited by this paper
• D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.

  1995cited by this paper
• Effects of electroconvulsive treatment on somatostattn, neuropeptide Y, endothelin, and neurokinin a concentrations in cerebrospinal fluid of depressed patients: A pilot study

  1995cited by this paper
• Are monoamine metabolites in cerebrospinal fluid worth measuring

  1993cited by this paper
• Depression in first-episode schizophrenia.

  1993cited by this paper
• The dopamine-serotonin relationship in clozapine response

  1993cited by this paper
• Are monoamine metabolites in cerebrospinal fluid worth measuring?

  1993cited by this paper
• Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.

  1993cited by this paper
• Falling off the straight line: some hazards of correlation and regression.

  1992cited by this paper
• Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

  1992cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Time Course for Effects of Sulpiride and Chlorpromazine on Monoamine Metabolite and Prolactin Levels in Cerebrospinal Fluid from Schizophrenic Patients

  1984cited by this paper
• Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment

  1978cited by this paper
• Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients

  1977cited by this paper
• 5-Hydroxyindoleacetic acid in spinal fluid: relative contribution from brain and spinal cord

  1973cited by this paper
• Sites of origin in the central nervous system of monoamine metabolites measured in human cerebrospinal fluid1

  1973cited by this paper
• 5-hydroxyindoleacetic cid in spinal fluid: relative contribution from brain and spinal cord.

  1973cited by this paper

• Anticholinergic Equivalence in Psychotropic Medications: A Guide for Psychiatrists.

  2025cites this paper
• The association between Inflammation and Kynurenine Pathway Metabolites in Electroconvulsive Therapy for Schizophrenia: Implications for Clinical Efficacy.

  2023cites this paper
• Differences in P-glycoprotein activity in human and rodent blood–brain barrier assessed by mechanistic modelling

  2021cites this paper
• A New Look on an Old Issue: Comprehensive Review of Neurotransmitter Studies in Cerebrospinal Fluid of Patients with Schizophrenia and Antipsychotic Effect on Monoamine’s Metabolism

  2021influential citation
• Norquetiapine blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner.

  2020cites this paper
• Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis

  2020cites this paper
• No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018cites this paper
• Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls

  2017cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder.

  2017cites this paper
• Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants

  2016cites this paper
• Associations between a locus downstream DRD1 gene and cerebrospinal fluid dopamine metabolite concentrations in psychosis.

  2016cites this paper
• Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid.

  2015cites this paper
• Current advances in biosampling for therapeutic drug monitoring of psychiatric CNS drugs.

  2015cites this paper
• Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia.

  2015influential citation
• Distribution pattern of mirtazapine and normirtazapine in blood and CSF

  2015influential citation
• Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model

  2015cites this paper
• Cerebrospinal fluid monoamine metabolite concentrations as intermediate phenotypes between glutamate-related genes and psychosis.

  2015cites this paper
• Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid.

  2015cites this paper
• Quetiapine Concentrations During Exclusive Breastfeeding and Maternal Quetiapine Use

  2015cites this paper
• Suicide attempt during late pregnancy with quetiapine: nonfatal outcome despite severe intoxication.

  2015cites this paper
• From the DEPARTMENT OF CLINICAL NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden MOLECULAR GENETIC STUDIES ON CEREBROSPINAL FLUID MONOAMINE METABOLITES IN PSYCHOTIC PATIENTS AND HEALTHY INDIVIDUALS

  2015influential citation
• Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis

  2014influential citation
• A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy

  2014cites this paper
• Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.

  2014cites this paper
• Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR.

  2013cites this paper
• Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000–2011

  2013cites this paper
• Utility of Combined Treatment with Antipsychotic and Antidepressant Drugs: Scientific Rationales and Clinical Implications

  2013cites this paper
• Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response.

  2012cites this paper
• d-amino acid oxidase activator gene (DAOA) variation affects cerebrospinal fluid homovanillic acid concentrations in healthy Caucasians

  2012influential citation
• Cognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial

  2012cites this paper
• Doxepin concentrations in plasma and cerebrospinal fluid

  2011cites this paper